An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
BOCA RATON, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Akron BioProducts, a leading manufacturer of cGMP-compliant technologies for cell and gene therapy, and Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced an agreement to develop and manufacture cGMP nucleases.
This collaboration strengthens Akron’s portfolio of off-the-shelf gene editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene modified cell therapies. Vor Bio continues to strategically invest in its proprietary manufacturing capabilities for its engineered HSC and CAR-T programs. The companies will collaborate in the development and manufacture of starting materials needed to advance potentially transformative treatments for blood cancers into the clinic.
“We are delighted to partner with the Vor Bio team, who share our patient-centered focus, leveraging Akron’s strengths in custom cGMP recombinant biologics to help accelerate Vor Bio’s pioneering treatment approach for blood cancers,” explained David Smith, President and Chief Commercial Officer at Akron BioProducts. “Collaborations like this are why we are developing a state-of-the-art cGMP facility for gene therapy and vaccine production to raise the bar on quality and safety.”
“This partnership with Akron strengthens and diversifies our global supply chain as we build out our new clinical manufacturing facility in Cambridge, MA, which we expect to be operational in 2022,” said Brent Morse, Vice President, Head of Process and Analytical Development at Vor Bio. “The facility will support both our eHSC and CAR-T product pipeline and will maximize flexibility while reducing the time and cost to manufacture cell therapy clinical candidates. The collaboration with Akron nicely complements this capability.”
About Akron
Akron BioProducts is a leading materials manufacturer and services provider to the regenerative medicine industry. An ISO 13485-certified company operating in line with cGMP guidelines and international standards, Akron leverages 110,000 square feet of development and manufacturing capacity to provide advanced therapy developers the scale, compliance, and regulatory support necessary to drive novel treatments from discovery to commercialization. For more information, please visit www.akronbiotech.com.
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
vor biopharma is pioneering engineered hematopoietic stem cells (ehscs) to dramatically change the treatment paradigm for hematological cancers. vor’s ehscs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. vor’s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and car-t cell treatments. a proof-of-concept study for vor’s lead program has been published in proceedings of the national academy of sciences. vor is based in cambridge, mass. and has a broad intellectual property base including in-licenses from columbia university, where foundational work was conducted by inventor and vor scientific board chair siddhar
